Martin Ried

Title: Martin Ried: Innovator in Adeno-Associated Virus Research

Introduction

Martin Ried is a notable inventor based in Sinning, Germany. He has made significant contributions to the field of virology, particularly in the study of adeno-associated viruses (AAV). With a total of 4 patents to his name, Ried's work focuses on enhancing the properties of these viruses for various applications.

Latest Patents

Among his latest patents is the invention titled "Structural protein of adeno-associated virus with modified antigenicity, its production and its use." This invention relates to a structural protein of AAV that includes modifications aimed at reducing its antigenicity, thereby improving its potential applications. Another significant patent is "AAv scleroprotein, production and use thereof," which describes a structural protein of AAV that has mutations to increase the virus's infectivity. These innovations highlight Ried's commitment to advancing the understanding and utility of AAV in medical research.

Career Highlights

Martin Ried is currently associated with Medigene AG, a company known for its focus on immunotherapy and innovative treatments. His work at Medigene AG has allowed him to explore the therapeutic potential of AAV in greater depth, contributing to the company's mission of developing cutting-edge medical solutions.

Collaborations

Ried has collaborated with esteemed colleagues such as Michael Hallek and Anne Girod. These partnerships have fostered a collaborative environment that enhances research outcomes and drives innovation in the field.

Conclusion

In summary, Martin Ried is a prominent inventor whose work on adeno-associated viruses has led to significant advancements in virology. His patents reflect a deep understanding of viral mechanisms and their potential applications in medicine.